Chemotherapy in Premenopausal Breast Cancer Patients

Ann H. Partridge

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

**Keywords**
Breast Cancer · Adjuvant chemotherapy · Premenopausal women · Long-term effects

**Summary**
Evidence has long demonstrated that premenopausal women obtain the greatest benefit from adjuvant chemotherapy overall, with risk reduction increasing with decreasing age. The chemoendocrine effect of chemotherapy has only more recently been documented as impacting on outcomes for women with hormone receptor-positive breast cancer, and recent data have elucidated the optimal strategies for manipulating the menopausal status to improve disease outcomes, without necessarily including cytotoxic chemotherapy. Still, many premenopausal women will require adjuvant cytotoxic chemotherapy, and the effects of breast cancer treatment on premenopausal women can profoundly impact not only on breast cancer outcomes but also on comorbidities and psychosocial outcomes [7, 8]. This article describes the most recent information and issues surrounding the indications, effects, and special considerations for adjuvant chemotherapy in premenopausal women with breast cancer, in an effort to inform their care.

**Indications for Adjuvant Chemotherapy**

Premenopausal women, and especially very young women (i.e., < 35 years of age), are more likely to present with more advanced disease than older women [9, 10]. They are also more likely to develop more aggressive subtypes of breast cancer with unfavorable prognostic features, and are less responsive to conventional therapy compared with disease arising in older premenopausal or postmenopausal women [11–13]. Tumors in younger women are more likely to be of high grade and HR negative; they have a high proliferation fraction and show more lymphovascular invasion. Younger women are also more likely to have human epidermal growth factor receptor 2 (HER2)-positive disease, with the highest incidence in the youngest women [13, 14]. For example, in the population-based California Cancer Registry data, Keegan et al. [13] reported the incidence of...
Chemotherapy Selection for Premenopausal Women

While the consideration of endocrine responsiveness should be the first consideration in tailoring adjuvant therapies for patients with breast cancer, regardless of menopausal status, adjuvant chemotherapy has been used extensively in premenopausal patients because of its overwhelming beneficial effects on outcome in certain patient subgroups [2]. As noted previously, premenopausal women are more likely to develop HER2-positive and triple-negative tumors compared with postmenopausal women, and the benefits of chemotherapy in these groups is well documented, regardless of menopausal status [22, 23]. Furthermore, women with luminal tumors appear to benefit from chemotherapy, although discerning for whom the benefits outweigh risks has been challenging [24].

For premenopausal women with HR-negative disease, adjuvant chemotherapy is a very important component of successful treatment. Studies have suggested that women with ER-negative disease garner the greatest benefits from incremental benefits from new chemotherapeutic strategies, and this does not appear to vary substantially with age or menopausal status. For example, women with ER-negative disease appeared to get the greatest benefit from the addition of paclitaxel to adriamycin and cytoxan and from giving the chemotherapy in a dose-dense fashion, in the Cancer and Leukemia Group B (CALGB) studies 9344 and 9741, respectively [25, 26]. One study has prospectively tested the use of chemotherapy in women with HR-negative, node-negative disease (National Surgical Adjuvant Breast and Bowel Project (NSABP) B13) [27]. Premenopausal women experienced a 38% reduction in the risk of recurrence from chemotherapy compared with surgery alone, and there was no difference between very young and older premenopausal women. Standard options for adjuvant chemotherapy for non-HER2-positive breast cancer are further detailed in current guidelines (www.NCCN.com).

Novel chemotherapeutic regimens (e.g., platinum agents) and biologics (e.g., poly(ADP-ribose) polymerase (PARP) inhibitors) that have shown promise in women with early and advanced disease may also be particularly relevant in the treatment of premenopausal women with ER-negative disease, given that this population is more likely to develop triple-negative disease and also more likely to harbor a BRCA1 or BRCA2 germline mutation [28–31].

The incremental benefits of the anti-HER2 therapy, trastuzumab, appear to be present across age groups, regardless of menopausal status [22, 23]. In an analysis of the HERceptin Adjuvant (HERA) trial including women with early-stage HER2-positive breast cancer, age was not strongly associated with risk of early recurrence or prediction of benefit from trastuzumab therapy [32]. Standard adjuvant chemotherapy and biologic options for HER2-positive disease are outlined in current guidelines (www.NCCN.com).

For premenopausal women with HR-positive disease, longstanding controversy has existed about optimal management. The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis regarding ovarian ablation revealed that the benefi-
cial effect of ovarian ablation was primarily seen only in the absence of chemotherapy, noting that more than 80% of the chemotherapy-alone group experiences amenorrhea with treatment [1, 33]. The International Breast Cancer Study Group (IBCSG) VIII study revealed that very young (<35 years old) women who received adjuvant chemotherapy alone for HR-positive tumors fared worse than older premenopausal women, leading to the recognition of and further validation studies on the chemoendocrine effect of chemotherapy in premenopausal women: Older premenopausal women are more likely to undergo chemotherapy-related ovarian dysfunction compared to young premenopausal women, resulting in improved disease outcomes in the setting of HR-positive breast cancer [3, 4, 34, 35]. Thus, the beneficial effects of chemotherapy in premenopausal women with HR-positive breast cancer are likely a result of a combination of cytotoxic and endocrine effects of chemotherapy.

Side Effects of Chemotherapy in Premenopausal Patients

Short-term symptoms and long-term or late effects of adjuvant chemotherapy should be considered in decision-making, treating and, in the long-term, follow-up care of premenopausal women with early-stage breast cancer. In general, premenopausal women tolerate chemotherapy as well as older women [8, 36]. However, the menopausal transition with therapy has been associated with both short- and long-term problems [7, 37]. Infertility, menopausal symptoms and sexual dysfunction, weight gain, body image concerns, and psychosocial distress are all common in premenopausal breast cancer survivors [38–40]. Research has, however, identified risk factors for sexual dysfunction in breast cancer survivors, including younger age, premature menopause, and the use of chemotherapy [41]. Fortunately, interventions to improve menopausal symptoms and sexual functioning have proven effective, with tailored specific attention focused on the problems and symptoms [42]. Guidelines to preserve fertility as well as psychosocial interventions exist to improve outcomes in patients with cancer and should be considered when caring for this vulnerable population (www.asco.org).

There are also numerous potential medical effects of premature menopause, including increased risks of weight gain, bone loss, cardiovascular disease, and dementia [43]. Attention to these issues, including prevention, screening and management, depending on the risk and the problem, in both short- and long-term follow-up is warranted (table 1).

Table 1. Special issues surrounding the treatment of premenopausal breast cancer patients with chemotherapy

- The benefits of chemotherapy treatment, particularly in light of potential benefits of optimal endocrine therapy, should be weighed against the potential risks.
- Selection of the chemotherapy regimen should depend on disease risk and phenotype as well as on patient preferences and comorbidities.
- Particular attention to menopausal symptoms and potential long-term risks of premature menopause is necessary.
- Premenopausal patients have an increased risk of distress in long- and short-term follow-up, warranting screening and treatment as needed.

Special Considerations

Premenopausal women with breast cancer face a variety of problems unique to or accentuated by their menopausal status and potential for a transition with treatment, and young age. In particular, younger women are more likely to be diagnosed at a time in life when roles at home or work may be disrupted by treatment, particularly when it includes chemotherapy. Furthermore, beauty, body image, and fertility may be of substantial importance for the younger population, all of which can be impaired by treatment. These concerns may contribute to the greater psychosocial distress seen in younger women at both diagnosis and in follow-up [7]. Women who undergo a menopausal transition with treatment may be particularly at risk. In a cross-sectional survey of 577 women ranging in age from 30 to 62 years, approximately 6 years after diagnosis – where nearly 75% had received adjuvant therapy – amenorrhea occurred frequently as a result of treatment in women ≥40 years at diagnosis [37]. Treatment-associated menopause was associated with poorer health perceptions. While the overall quality of life (QOL) in premenopausal breast cancer survivors is generally good, there is clearly substantial symptomatology and risk of increased emotional disruption, especially among women experiencing a menopausal transition as part of the therapy [37, 44]. Thus, treating premenopausal women with adjuvant breast cancer chemotherapy warrants not only attention to the myriad short- and long-term side effects and medical risks but also to the potential for emotional distress, and screening and appropriate intervention for the psychosocial aftermath of treatment comprise an important component of high-quality cancer care [45].

Disclosure Statement

The author has no conflicts of interest to disclose.
References


